Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Roboz

Showing results (201-210 of 276) with videos related to

Pageof 28
Sort By:
Leukemia|June 13, 2008
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemiaE J Feldman, J Cortes, D J DeAngelo, et al.
Cancer|June 27, 2025
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment ConsortiumMichael Boyiadzis, Andrew H Wei, Bruno Paiva, et al.
Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.
Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.
The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.
Haematologica|September 23, 2021
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trialGail J Roboz, Hartmut Döhner, Christopher Pocock, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDSRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Blood Advances|December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trialJane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Pageof 28

Showing results (201-210 of 276) with videos related to

Sort By:
Pageof 28
Leukemia|June 13, 2008
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemiaE J Feldman, J Cortes, D J DeAngelo, et al.
Cancer|June 27, 2025
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment ConsortiumMichael Boyiadzis, Andrew H Wei, Bruno Paiva, et al.
Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.
Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.
The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.
Haematologica|September 23, 2021
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trialGail J Roboz, Hartmut Döhner, Christopher Pocock, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDSRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Blood Advances|December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trialJane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Pageof 28